<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00159783</url>
  </required_header>
  <id_info>
    <org_study_id>P05857</org_study_id>
    <secondary_id>A7501007</secondary_id>
    <nct_id>NCT00159783</nct_id>
  </id_info>
  <brief_title>40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)</brief_title>
  <official_title>A Double-Blind, 40-Week Continuation Study Evaluating the Safety of Asenapine and Olanzapine in the Treatment of Subjects With Acute Mania Clinical Trial Protocol A7501007 (Secondary Title: ARES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bipolar disorder is characterized by mood swings that range from from high (manic) to low
      (depressed) states. Sometimes, symptoms of both depression and mania are present (mixed
      episodes). Asenapine is an investigational medication for the treatment of manic or mixed
      episodes of bipolar disorder. Patients who completed study A7501006 (a 9 week extension
      study) could continue with the same treatment that they had been receiving: asenapine or
      olanzapine (a medication that is already approved for the treatment of bipolar mania) in a 40
      -week continuation study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants Who Experienced Adverse Event(s)</measure>
    <time_frame>Up to 40 weeks</time_frame>
    <description>Adverse event (AE) data, both serious and non-serious, were collected. Serious AEs were also collected up to 30 days post last dose of study drug.
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product. It does not necessarily have to have a causal relationship with this treatment.
An AE is defined as serious if it results in death, is life-threatening, requires in-patient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Physical Examination Findings</measure>
    <time_frame>Week 40 or endpoint</time_frame>
    <description>Physical exam (PE) included assessment of general appearance, skin, head, eyes, ears, nose, throat, lungs, blood pressure, cardiac rhythm &amp; rate, neurologic status, and abdomen. The findings were deemed to be normal/abnormal based on the clinical judgment of the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram</measure>
    <time_frame>Week 40 or endpoint</time_frame>
    <description>This is the number of participants with electrocardiogram (ECG) adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Weight</measure>
    <time_frame>Baseline to Week 40 or endpoint</time_frame>
    <description>Weight change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extrapyramidal Symptoms [EPS]</measure>
    <time_frame>Week 40 or endpoint</time_frame>
    <description>EPS was assessed using the (1) involuntary movement scale [AIMS], (2) Barnes Akathisia Rating Scale [BARS], and (3) Simpson Angus Rating Scale SARS.
AIMS score range 0-4; higher scores indicate greater symptom severity.
BARS score rang 0-9; higher scores indicate greater severity of akathisia.
SARS score range 0-40; higher scores indicate greater degree of Parkinsonism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concomitant Medications</measure>
    <time_frame>Up to 40 weeks</time_frame>
    <description>Concomitant medications are any medications taken on or after the date of first dose of double-blind study drug through the date of
last dose of double-blind study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abdominal Girth</measure>
    <time_frame>Baseline to Week 40 or endpoint</time_frame>
    <description>Change in abdominal girth from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Markedly Abnormal Vital Sign Changes</measure>
    <time_frame>Post-baseline (at Week 4, 12, 20, 28, and 40 or endpoint)</time_frame>
    <description>Vital signs measured: sitting blood pressure, heart rate.
Definitions:
Markedly abnormal decreases: heart rate (HR) - if ≤50 bpm and decrease from baseline of ≥15 beats per minute (bpm); systolic blood pressure (SBP) - if ≤90 mm Hg and decrease from baseline of ≥20 mm Hg; diastolic blood pressure (DBP) - if ≤50 mm Hg and decrease from baseline of ≥15 mm Hg.
Markedly abnormal increases: HR - if ≥110 bpm and increase from baseline of ≥15 bpm; SBP - if ≥180 mm Hg and increase from baseline of ≥20 mm Hg; DBP - if ≥105 mm Hg and increase from baseline of ≥15 mm Hg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Values Outside Normal Range</measure>
    <time_frame>Week 40 or endpoint</time_frame>
    <description>Normal ranges were provided by the central laboratory.
Biochemistry = electrolytes, creatine kinase, liver enzymes, blood urea nitrogen, creatinine, alkaline phosphatase, protein, albumin
Metabolic chemistry = cholesterol, glucose, triglycerides, glycosylated hemoglobin
Endocrinology/miscellaneous = insulin, prolactin
Hematology = hemoglobin, red blood cell count, white blood cell count, platelets, hematocrit, neutrophils, lymphocytes, monocytes, eosinophils, basophils</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Asenapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asenapine 5-10 mg twice daily for 40 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olanzapine 5-20 mg once daily for 40 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asenapine</intervention_name>
    <description>Asenapine, 40 weeks</description>
    <arm_group_label>Asenapine</arm_group_label>
    <other_name>Org 5222</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine, 40 weeks</description>
    <arm_group_label>Olanzapine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have completed asenapine 3-week and 9 -week studies for the treatment of an acute
             manic or mixed episode and not had any major protocol violations..

        Exclusion Criteria:

          -  Patients with unstable medical conditions or clinically significant laboratory

        abnormalities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Bulgaria</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord. 2010 Nov;126(3):358-65. doi: 10.1016/j.jad.2010.04.005.</citation>
    <PMID>20537396</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <results_first_submitted>April 15, 2010</results_first_submitted>
  <results_first_submitted_qc>June 17, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2010</results_first_posted>
  <last_update_submitted>February 6, 2015</last_update_submitted>
  <last_update_submitted_qc>February 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Asenapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo/Asenapine</title>
          <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on placebo during the 3 week core study)</description>
        </group>
        <group group_id="P2">
          <title>Asenapine</title>
          <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on asenapine in the 3 week core study)</description>
        </group>
        <group group_id="P3">
          <title>Olanzapine</title>
          <description>Olanzapine 5-20 mg once daily for 40 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo/Asenapine</title>
          <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on placebo during the 3 week core study)</description>
        </group>
        <group group_id="B2">
          <title>Asenapine</title>
          <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on asenapine in the 3 week core study)</description>
        </group>
        <group group_id="B3">
          <title>Olanzapine</title>
          <description>Olanzapine 5-20 mg once daily for 40 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="107"/>
            <count group_id="B4" value="218"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants Who Experienced Adverse Event(s)</title>
        <description>Adverse event (AE) data, both serious and non-serious, were collected. Serious AEs were also collected up to 30 days post last dose of study drug.
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product. It does not necessarily have to have a causal relationship with this treatment.
An AE is defined as serious if it results in death, is life-threatening, requires in-patient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.</description>
        <time_frame>Up to 40 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Asenapine</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on placebo during the 3 week core study)</description>
          </group>
          <group group_id="O2">
            <title>Asenapine</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on asenapine in the 3 week core study)</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine</title>
            <description>Olanzapine 5-20 mg once daily for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Experienced Adverse Event(s)</title>
          <description>Adverse event (AE) data, both serious and non-serious, were collected. Serious AEs were also collected up to 30 days post last dose of study drug.
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product. It does not necessarily have to have a causal relationship with this treatment.
An AE is defined as serious if it results in death, is life-threatening, requires in-patient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Physical Examination Findings</title>
        <description>Physical exam (PE) included assessment of general appearance, skin, head, eyes, ears, nose, throat, lungs, blood pressure, cardiac rhythm &amp; rate, neurologic status, and abdomen. The findings were deemed to be normal/abnormal based on the clinical judgment of the investigator.</description>
        <time_frame>Week 40 or endpoint</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Treatment Groups</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks or Olanzapine 5-20 mg daily for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Physical Examination Findings</title>
          <description>Physical exam (PE) included assessment of general appearance, skin, head, eyes, ears, nose, throat, lungs, blood pressure, cardiac rhythm &amp; rate, neurologic status, and abdomen. The findings were deemed to be normal/abnormal based on the clinical judgment of the investigator.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Electrocardiogram</title>
        <description>This is the number of participants with electrocardiogram (ECG) adverse events.</description>
        <time_frame>Week 40 or endpoint</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Asenapine</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on placebo during the 3 week core study)</description>
          </group>
          <group group_id="O2">
            <title>Asenapine</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on asenapine in the 3 week core study)</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine</title>
            <description>Olanzapine 5-20 mg once daily for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Electrocardiogram</title>
          <description>This is the number of participants with electrocardiogram (ECG) adverse events.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sinus bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bundle branch block right</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG QRS complex prolonged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG ST segment depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG T wave inversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supraventricular extrasystoles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventricular extrasystoles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Body Weight</title>
        <description>Weight change from baseline</description>
        <time_frame>Baseline to Week 40 or endpoint</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Asenapine</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on placebo during the 3 week core study)</description>
          </group>
          <group group_id="O2">
            <title>Asenapine</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on asenapine in the 3 week core study)</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine</title>
            <description>Olanzapine 5-20 mg once daily for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight</title>
          <description>Weight change from baseline</description>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" spread="19.94"/>
                    <measurement group_id="O2" value="68.1" spread="17.22"/>
                    <measurement group_id="O3" value="72.0" spread="19.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Week 40 or endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="5.95"/>
                    <measurement group_id="O2" value="3.5" spread="6.65"/>
                    <measurement group_id="O3" value="6.0" spread="6.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Extrapyramidal Symptoms [EPS]</title>
        <description>EPS was assessed using the (1) involuntary movement scale [AIMS], (2) Barnes Akathisia Rating Scale [BARS], and (3) Simpson Angus Rating Scale SARS.
AIMS score range 0-4; higher scores indicate greater symptom severity.
BARS score rang 0-9; higher scores indicate greater severity of akathisia.
SARS score range 0-40; higher scores indicate greater degree of Parkinsonism.</description>
        <time_frame>Week 40 or endpoint</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Asenapine</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on placebo during the 3 week core study)</description>
          </group>
          <group group_id="O2">
            <title>Asenapine</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on asenapine in the 3 week core study)</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine</title>
            <description>Olanzapine 5-20 mg once daily for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Extrapyramidal Symptoms [EPS]</title>
          <description>EPS was assessed using the (1) involuntary movement scale [AIMS], (2) Barnes Akathisia Rating Scale [BARS], and (3) Simpson Angus Rating Scale SARS.
AIMS score range 0-4; higher scores indicate greater symptom severity.
BARS score rang 0-9; higher scores indicate greater severity of akathisia.
SARS score range 0-40; higher scores indicate greater degree of Parkinsonism.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AIMS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.37"/>
                    <measurement group_id="O2" value="0.1" spread="0.60"/>
                    <measurement group_id="O3" value="0.0" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BARS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.21"/>
                    <measurement group_id="O2" value="0.2" spread="0.77"/>
                    <measurement group_id="O3" value="0.1" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SARS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.72"/>
                    <measurement group_id="O2" value="0.2" spread="1.36"/>
                    <measurement group_id="O3" value="0.3" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concomitant Medications</title>
        <description>Concomitant medications are any medications taken on or after the date of first dose of double-blind study drug through the date of
last dose of double-blind study drug.</description>
        <time_frame>Up to 40 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Asenapine</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on placebo during the 3 week core study)</description>
          </group>
          <group group_id="O2">
            <title>Asenapine</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on asenapine in the 3 week core study)</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine</title>
            <description>Olanzapine 5-20 mg once daily for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Concomitant Medications</title>
          <description>Concomitant medications are any medications taken on or after the date of first dose of double-blind study drug through the date of
last dose of double-blind study drug.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with no concomitant medications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with &gt;=1 concomitant medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Abdominal Girth</title>
        <description>Change in abdominal girth from baseline</description>
        <time_frame>Baseline to Week 40 or endpoint</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Asenapine</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on placebo during the 3 week core study)</description>
          </group>
          <group group_id="O2">
            <title>Asenapine</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on asenapine in the 3 week core study)</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine</title>
            <description>Olanzapine 5-20 mg once daily for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Abdominal Girth</title>
          <description>Change in abdominal girth from baseline</description>
          <units>Centimeters (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1" spread="14.20"/>
                    <measurement group_id="O2" value="86.8" spread="14.79"/>
                    <measurement group_id="O3" value="89.4" spread="14.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Week 40 or endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="6.84"/>
                    <measurement group_id="O2" value="2.6" spread="6.87"/>
                    <measurement group_id="O3" value="5.0" spread="7.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Markedly Abnormal Vital Sign Changes</title>
        <description>Vital signs measured: sitting blood pressure, heart rate.
Definitions:
Markedly abnormal decreases: heart rate (HR) – if ≤50 bpm and decrease from baseline of ≥15 beats per minute (bpm); systolic blood pressure (SBP) – if ≤90 mm Hg and decrease from baseline of ≥20 mm Hg; diastolic blood pressure (DBP) – if ≤50 mm Hg and decrease from baseline of ≥15 mm Hg.
Markedly abnormal increases: HR – if ≥110 bpm and increase from baseline of ≥15 bpm; SBP – if ≥180 mm Hg and increase from baseline of ≥20 mm Hg; DBP – if ≥105 mm Hg and increase from baseline of ≥15 mm Hg.</description>
        <time_frame>Post-baseline (at Week 4, 12, 20, 28, and 40 or endpoint)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Asenapine</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on placebo during the 3 week core study)</description>
          </group>
          <group group_id="O2">
            <title>Asenapine</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on asenapine in the 3 week core study)</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine</title>
            <description>Olanzapine 5-20 mg once daily for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Markedly Abnormal Vital Sign Changes</title>
          <description>Vital signs measured: sitting blood pressure, heart rate.
Definitions:
Markedly abnormal decreases: heart rate (HR) – if ≤50 bpm and decrease from baseline of ≥15 beats per minute (bpm); systolic blood pressure (SBP) – if ≤90 mm Hg and decrease from baseline of ≥20 mm Hg; diastolic blood pressure (DBP) – if ≤50 mm Hg and decrease from baseline of ≥15 mm Hg.
Markedly abnormal increases: HR – if ≥110 bpm and increase from baseline of ≥15 bpm; SBP – if ≥180 mm Hg and increase from baseline of ≥20 mm Hg; DBP – if ≥105 mm Hg and increase from baseline of ≥15 mm Hg.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Values Outside Normal Range</title>
        <description>Normal ranges were provided by the central laboratory.
Biochemistry = electrolytes, creatine kinase, liver enzymes, blood urea nitrogen, creatinine, alkaline phosphatase, protein, albumin
Metabolic chemistry = cholesterol, glucose, triglycerides, glycosylated hemoglobin
Endocrinology/miscellaneous = insulin, prolactin
Hematology = hemoglobin, red blood cell count, white blood cell count, platelets, hematocrit, neutrophils, lymphocytes, monocytes, eosinophils, basophils</description>
        <time_frame>Week 40 or endpoint</time_frame>
        <population>Number at risk = participants with either normal or abnormal baseline value and a non-missing value at endpoint.
Actual at risk: 20-32 for placebo/asenapine arm; 50-78 for asenapine arm; 63-106 in olanzapine arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Asenapine</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on placebo during the 3 week core study)</description>
          </group>
          <group group_id="O2">
            <title>Asenapine</title>
            <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on asenapine in the 3 week core study)</description>
          </group>
          <group group_id="O3">
            <title>Olanzapine</title>
            <description>Olanzapine 5-20 mg once daily for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Values Outside Normal Range</title>
          <description>Normal ranges were provided by the central laboratory.
Biochemistry = electrolytes, creatine kinase, liver enzymes, blood urea nitrogen, creatinine, alkaline phosphatase, protein, albumin
Metabolic chemistry = cholesterol, glucose, triglycerides, glycosylated hemoglobin
Endocrinology/miscellaneous = insulin, prolactin
Hematology = hemoglobin, red blood cell count, white blood cell count, platelets, hematocrit, neutrophils, lymphocytes, monocytes, eosinophils, basophils</description>
          <population>Number at risk = participants with either normal or abnormal baseline value and a non-missing value at endpoint.
Actual at risk: 20-32 for placebo/asenapine arm; 50-78 for asenapine arm; 63-106 in olanzapine arm.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Biochemistry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolic chemistry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrinology/miscellaneous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo/Asenapine</title>
          <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on placebo during the 3 week core study)</description>
        </group>
        <group group_id="E2">
          <title>Asenapine</title>
          <description>Asenapine 5-10 mg twice daily for 40 weeks (participants who were on asenapine in the 3 week core study)</description>
        </group>
        <group group_id="E3">
          <title>Olanzapine</title>
          <description>Olanzapine 5-20 mg once daily for 40 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (9.1)">Death neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (9.1)">Drug exposure during pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (9.1)">Bipolar I disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E3" events="14" subjects_affected="7" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If study is part of a multicenter trial, Investigator agrees that the first publication is to be a joint publication covering all centers. However, if a joint manuscript has not been submitted for publication within 12 mos of completion or termination of study at all participating sites, Investigator is free to publish separately.
The sponsor should review any publication prior to submission for publication to ensure no confidential information is released inadvertently.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

